Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-06-14
2011-06-14
Bunner, Bridget E (Department: 1649)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
Reexamination Certificate
active
07960343
ABSTRACT:
In certain aspects, the present invention provides compositions and methods for decreasing FSH levels in a patient. The patient may, for example, be diagnosed with an FSH-related disorder or desire to delay or inhibit germ cell maturation.
REFERENCES:
patent: 4973577 (1990-11-01), Vale, Jr. et al.
patent: 5118667 (1992-06-01), Adams et al.
patent: 5658876 (1997-08-01), Crowley et al.
patent: 5824637 (1998-10-01), Crowley et al.
patent: 5847078 (1998-12-01), Eto et al.
patent: 5885794 (1999-03-01), Mathews et al.
patent: 6093547 (2000-07-01), Jin et al.
patent: 6132988 (2000-10-01), Sugino et al.
patent: 6162896 (2000-12-01), Mathews et al.
patent: 6451334 (2002-09-01), Perrine
patent: 6599876 (2003-07-01), Kojima
patent: 6605699 (2003-08-01), Ni et al.
patent: 6656475 (2003-12-01), Lee et al.
patent: 6692925 (2004-02-01), Miyazono et al.
patent: 6696260 (2004-02-01), Lee et al.
patent: 6835544 (2004-12-01), Mathews et al.
patent: 6891082 (2005-05-01), Lee et al.
patent: 7192717 (2007-03-01), Hill et al.
patent: 7202210 (2007-04-01), Wolfman et al.
patent: 7261893 (2007-08-01), Veldman et al.
patent: 7320789 (2008-01-01), Aghajanian et al.
patent: 7560441 (2009-07-01), Wolfman et al.
patent: 7612041 (2009-11-01), Knopf et al.
patent: 2003/0083251 (2003-05-01), Westenfelder
patent: 2003/0144203 (2003-07-01), Bowen
patent: 2004/0197828 (2004-10-01), Gaddy
patent: 2004/0209805 (2004-10-01), Phillips et al.
patent: 2004/0223966 (2004-11-01), Wolfman et al.
patent: 2005/0257278 (2005-11-01), Lee et al.
patent: 2006/0068468 (2006-03-01), Knopf et al.
patent: 2006/0210657 (2006-09-01), Chou
patent: 2007/0048830 (2007-03-01), Gilbert et al.
patent: 2007/0149455 (2007-06-01), Wolfman et al.
patent: 2007/0172956 (2007-07-01), Magari et al.
patent: 2007/0184052 (2007-08-01), Lin et al.
patent: 2007/0249022 (2007-10-01), Knopf et al.
patent: 2007/0275895 (2007-11-01), Duan et al.
patent: 2007/0292885 (2007-12-01), Bejanin et al.
patent: 2008/0021104 (2008-01-01), Tarallo
patent: 2008/0075692 (2008-03-01), Perrine
patent: 2008/0089897 (2008-04-01), Wolfman
patent: 2008/0139590 (2008-06-01), Qian et al.
patent: 2009/0005308 (2009-01-01), Knopf et al.
patent: 2009/0017019 (2009-01-01), Shields et al.
patent: 2009/0047281 (2009-02-01), Sherman
patent: 2009/0074768 (2009-03-01), Knopf et al.
patent: 2009/0087433 (2009-04-01), Wolfman et al.
patent: 2009/0098113 (2009-04-01), Knopf et al.
patent: 2009/0099086 (2009-04-01), Knopf et al.
patent: 2009/0118188 (2009-05-01), Knopf et al.
patent: 2009/0142333 (2009-06-01), Knopf et al.
patent: 2009/0148436 (2009-06-01), LaVallie et al.
patent: 2009/0163417 (2009-06-01), Sherman
patent: 1174149 (2002-01-01), None
patent: WO-92/20793 (1992-11-01), None
patent: WO-95/10611 (1995-04-01), None
patent: WO95/29685 (1995-11-01), None
patent: WO-99/06559 (1999-02-01), None
patent: WO-00/43781 (2000-07-01), None
patent: WO-02/10214 (2002-02-01), None
patent: WO-02/43759 (2002-06-01), None
patent: WO-02/085306 (2002-10-01), None
patent: WO-03/006057 (2003-01-01), None
patent: WO03/053219 (2003-07-01), None
patent: WO-03/072808 (2003-09-01), None
patent: WO-2004/039948 (2004-05-01), None
patent: WO-2004108157 (2004-12-01), None
patent: WO-2005/009460 (2005-02-01), None
patent: WO-2005/028517 (2005-03-01), None
patent: WO-2005/097825 (2005-10-01), None
patent: WO-2005094871 (2005-10-01), None
patent: WO-2006002387 (2006-01-01), None
patent: WO-2006/012627 (2006-02-01), None
patent: WO-2006020884 (2006-02-01), None
patent: WO-2006039400 (2006-04-01), None
patent: WO-2006083183 (2006-08-01), None
patent: WO-2006088972 (2006-08-01), None
patent: WO-2007/062188 (2007-05-01), None
patent: WO-2007053775 (2007-05-01), None
patent: WO-2007067616 (2007-06-01), None
patent: WO-2008031061 (2008-03-01), None
patent: WO-2008060139 (2008-05-01), None
patent: WO-2008076437 (2008-06-01), None
patent: WO-2008097541 (2008-08-01), None
patent: WO-2008100384 (2008-08-01), None
patent: WO-2008109167 (2008-09-01), None
patent: WO-2009019504 (2009-02-01), None
patent: WO-2009019505 (2009-02-01), None
patent: WO-2009137613 (2009-11-01), None
Website downloaded on Jun. 14, 2010, about.com/reports/000101—2.htm?p=1; 11 pages total.
Harrison et al., JBC, 2004; 279: 28036-28044.
Raju et al., Biochem Biophys Res Commun. 2006; 341: 797-803.
Gregoriadis et al., FEBS, 1993; 314: 271-276.
Acceleron Pharma Presents Positive Phase 1 Results Demonstrating ACE-011 Increases Markers of Bone Formation, Acceleron Pharma, pp. 1-2, retrieved from the Internet, www.acceleronpharma.com/contents
ews/press-releases/detail.jsp/q
ews-id/47> (2007).
Akel et al., Neutralization of Autocrine Transforming Growth Factor -β in Human Cord Blood CD34+CD38-Lin—Cells Promotes Stem-Cell-Factor-Mediated Erythropoietin-Independent Early Erythroid Progenitor Development and Reduces Terminal Differentiation. Stem Cells vol. 21; pp. 557-567 (2003).
Akpan, I., et al., “The effects of a soluble activin type IIB receptor on obesity and insulin sensitivity,” International Journal of Obesity, 33(11):1265-1273 (2009), Published Nov. 2009, Advance online publication date was Aug. 11, 2009, Abstract, pp. 1266, 1269.
Broxmeyer, H.E., et al, “Selective and indirect modulation of human multipotential and erythroid hematopoietic progenitor cell proliferation by recombinant human activin and inhibin,” Proc. Natl. Acad. Sci. USA, 85:9052-9056 (1988).
Burdette et al., Activin A mediates growth inhibition and cell cycle arest through Smads in human breast cancer cells. Cancer Research, 65(17):7968-7975; Abstract (2005).
Centrella et al., “Activin-A Binding and Biochemical Effects in Osteoblast-Enriched Cultures from Fetal-Rat Parietal Bone,” Molecular and Cellular Biology, 11(1):250-58 (1991).
Chen, Y.G., et al. “Regulation of Cell Proliferation, Apoptosis, and Carcinogenesis by Activin,” Exp. Biol. Med., 227(2):75-87 (2002).
Coerver, et al., “Activin Signaling through Activin Receptor Type II Causes the Cachexia-Like Symptoms in Inhibin-Deficent Mice,” 10(5):534-543 (1996).
Daluiski et al., “Bone Morphogenetic Protein-3 is a Negative Regulator of Bone Density,” Nature Genetics, 27:84-88 (2001).
del Re et al., “Reconstitution and Analysis of Soluble Inhibin and Activin Receptor Complexes in a Cell-free System,” The Journal of Biological Chemistry, 279(51):53126-53135 (2004).
Donaldson, et al., “Activin and inhibin binding to the soluble extracellular domain of activin receptor II”, Endocrinology 140(4):1760-1766(1999).
Donaldson, et al., “Molecular Cloning and Binding Properties of the Human Type II Activin Receptor”, Biochemical and Biophysical Research Communications, 184(1):310-316(1992).
Fafioffe, et al.,“Activin and inhibin receptor gene expression in the ewe pituitary throughout the oestrous cycle,” Journal of Endocrinology, vol. 182, pp. 55-68 (2004).
Frigon, N.L., et al, “Regulation of Globin Gene Expression in Human K562 Cells by Recombinant Activin A,” Blood, 79(3):765-772 (1992).
Fuller et al., “Activin A Is an Essential Cofactor for Osteoclast Induction,” Biochemical and Biophysical Research Communications, 268:2-7 (2000).
Funaba et al., “Expression and Localization of Activin Receptors During Endochondral Bone Development,” European Journal of Endocrinology, 144:63-71 (2001).
Gaddy-Kurten et al., “Inhibin Suppresses and Activin Stimulates Osteoblastogenesis and Osteoclastogenesis in Murine Bone Marrow Cultures,” Endocrinology, 143(1):74-83 (2002).
Gamer et al., “BMP-3 is a Novel Inhibitor of Both Activin and BMP-4 Signaling in Xenopus Embryos,” Developmental Biology, 285:156-168 (2005).
Ge, G., et al., “GDF11 Forms a Bone Morphogenetic Protein 1-Activated Latent Complex That Can Modulate Nerve Growth Factor-Induced Differentiation of PC12 Cells”, Molecular and Cellular Biology, 25(14):5846-5858 (2005).
GenBank NM—001106, Homo sapiens activin A receptor, type IIB (ACVR2B), mRNA
Knopf John
Seehra Jasbir
Sherman Matthew L.
Acceleron Pharma Inc.
Borgeest Christina
Bunner Bridget E
Ropes & Gray LLP
LandOfFree
Activin-ActRIIa antagonists and uses for decreasing or... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Activin-ActRIIa antagonists and uses for decreasing or..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Activin-ActRIIa antagonists and uses for decreasing or... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2719742